Navigation Links
Aethlon Medical Announces Biotech Showcase™ 2012 Presentation
Date:1/4/2012

SAN DIEGO, Jan. 4, 2012 /PRNewswire/-- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that its Chairman and CEO James A. Joyce will be the lead-off presenter at the Biotech Showcase™ 2012. Mr. Joyce's presentation will begin at 9:00 am Pacific Time on January 9th, 2012.  A live webcast of the presentation will be available at:

http://www.media-server.com/m/p/dfvbu2du

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

About Biotech Showcase™

Biotech Showcase™ is a forum devoted to providing biotechnology companies, investors and pharmaceutical executives with an opportunity to meet in one place during the course of one of the world's largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.

Now in its fourth year, this rapidly growing financial-focused biotech conference features multiple tracks of presenting companies, plenary sessions, an opportunity to schedule one-to-one partnering meetings and networking. The attendees to the showcase include private and public equity investors, analysts, bankers, biopharmaceutical industry executives and other industry professionals.  The event is being held at the Parc 55 Wyndham San Francisco – Union Square. 

About Aethlon Medical

The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Contacts:

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com

 

 

 

 


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
2. Aethlon Medical Releases Shareholder Letter
3. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
4. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
5. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
6. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
7. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
8. Aethlon Medical Releases Shareholder Letter
9. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
10. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
11. Aethlon Medical Clarifies News Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... MARLTON, N.J. , April 28, 2016   ... solutions, today announced that leading IT market research and ... Player " in the IDC MarketScape: Worldwide Pharmaceutical Track ... March 2016).  The report provides an assessment of the ... pharmaceutical track and trace software market. Logo ...
(Date:4/27/2016)... 2016  Hologic, Inc. (Nasdaq: HOLX ... the fiscal second quarter ended March 26, 2016.  ... increased 41.2%, and non-GAAP diluted EPS of $0.47 ... on a reported basis, and 6.3% on a ... another good quarter, highlighted by 14.6% growth in ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion ... established an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data ... October 1, 2016. , Sarcopenia is defined as a combination of low muscle mass ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... affected by a health insurance co-operative bankruptcy to receive their prescription medications ... receive over 1,500 FDA-approved prescription medications from over 180 American pharmaceutical companies ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... announced its latest offering, the Protocol Calendar Exchange , is officially open ... pre-built, pre-reviewed protocol calendars available for sites to download into their clinical trial ...
(Date:4/28/2016)... Vail, Colorado (PRWEB) , ... April 28, 2016 ... ... LaPrade, MD, PhD, Chief Medical Officer at the Steadman Philippon Research Institute ... Capitol Hill Day to raise awareness about the debilitating and costly musculoskeletal ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... intelligent business communication applications and infrastructure for telecommunication service providers is pleased ... at Bestel’s Communications Network. The ACONYX Number Portability solution fully meets ...
Breaking Medicine News(10 mins):